Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

Abstract

In a retrospective cohort study of 170 heart, liver, and kidney transplant recipients, secondary prophylaxis with valganciclovir following treatment of cytomegalovirus disease was not shown to have any sustained benefit on the likelihood of relapse.